Surgical Graft Market Size, Share & Analysis | Global | 2025-2032 | Includes: Lower Limb Surgical Grafts, and 2 more

Global Surgical Graft Market Report

The global surgical graft market was valued at $206 million in 2025. Over the forecast period, the market is expected to grow at a CAGR of 0.6% to reach $215 million by 2032.

• The full report suite on the global market for surgical grafts covers seven geographical regions: North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa. For each region, the report provides market valuation, unit analysis and average selling price data, along with forecasts through 2032 and historical data to 2022. As with the attached example document, this description follows the same structured sequence from executive summary through market dynamics, segmentation, competition and deliverables, adapted to the specific conditions of the surgical graft market .

This report provides a focused analysis of the global surgical graft market, including unit sales, procedure numbers, average selling prices, total market value, market shares, growth rates and market forecasts. It also includes market drivers and limiters, recent mergers and acquisitions, company profiles, product portfolios and analysis of leading competitors. The market is further segmented by indication into lower limb, aorta repair and extra-anatomical bypass procedures.

Overall, the global surgical graft market is best understood as a stable but constrained segment. It is no longer a major growth engine within vascular intervention, but it remains clinically necessary in selected procedures and patient populations. That gives the market ongoing strategic importance even as minimally invasive techniques continue reshaping vascular care.

Market Overview

The global surgical graft market includes synthetic vascular grafts used in open surgical procedures to replace, bypass or reconstruct diseased blood vessels. These grafts are used in several major clinical settings, including lower-limb bypass, aortic repair and extra-anatomical bypass procedures. In many of these cases, surgical grafts are selected when disease severity, anatomy or patient condition limits the use of alternative therapies.

This market exists within a vascular treatment landscape that has changed significantly over time. In earlier periods, open vascular surgery played a much larger role across many indications. Today, a growing number of patients are treated using endovascular methods such as angioplasty, stenting and stent graft placement. These minimally invasive approaches have changed referral patterns, altered treatment algorithms and reduced the number of cases in which open surgical graft implantation is the default option.

Even so, surgical grafts remain relevant because not all patients are good candidates for endovascular repair. Some present with advanced disease, difficult anatomy or clinical circumstances that limit the use of stent grafts, bypass alternatives or autologous veins. In these cases, surgical grafts remain necessary. This is especially true in aortic repair and in selected lower-limb bypass procedures where durable reconstruction is required and where the patient's anatomy or disease burden narrows the treatment options.

Overall, the global surgical graft market reflects a combination of mature procedural demand, selective clinical necessity and competitive pressure from newer vascular technologies. That combination explains why the market continues to exist with steady value, but only modest growth.

Market Drivers

Hemodialysis Patients

One of the most important drivers in the global surgical graft market is the growing population of hemodialysis patients. As the number of patients requiring long-term dialysis increases worldwide, demand for AV access surgical grafts also grows. These grafts remain an important part of access management, particularly in patients who are not suitable candidates for fistula creation or whose anatomy limits other access options.

This driver is especially important because fistula placement has already reached high penetration in much of Europe. Since fistulas have already taken a large share of appropriate cases, further cannibalization of the AV access surgical graft market is more limited than it was in earlier periods. That leaves surgical grafts with a more stable role in the hemodialysis setting, particularly in patients with more complex access needs.

Increased Prevalence of Aneurysms

The increasing prevalence of aneurysms is another important market driver. Surgical interventions, including vascular graft implantation, are often reserved for patients with more advanced disease states. In many of these cases, patients have limited endovascular or bypass graft options and still require open repair. As the global population continues to age, the number of patients who fall into this category is expected to increase.

This aging effect supports demand in aortic repair and other major vascular reconstruction procedures. Even though endovascular repair has become more common, open surgical graft implantation remains necessary in a meaningful subset of aneurysm cases. This provides continued procedural support for the surgical graft market over the forecast period.

Healthcare Spending Cuts and Cost Sensitivity

Budget constraints in hospitals and health systems also support demand for surgical grafts in certain regions. In several countries, especially in parts of Eastern Europe, cost pressure has slowed the adoption of stent grafts and favored the continued use of less expensive surgical grafts. This is not because surgical procedures are easier or less invasive, but because the total economic burden of stent graft use can be higher.

In addition to the higher device cost of stent grafts, endovascular repair often carries follow-up costs that can add to the overall treatment burden. Evidence from teams involved in the EVAR I trial showed that total hospital costs associated with endovascular repair were significantly higher than those associated with open repair. In price-sensitive healthcare systems, this difference can influence treatment choice and help preserve the role of surgical grafts.

Market Limiters

Alternative Endovascular Procedures

The biggest limiter in the global surgical graft market is the availability of alternative endovascular procedures. Stent placement and balloon angioplasty offer less invasive treatment paths and are associated with shorter procedure times, lower patient trauma and often fewer complications than full surgical repair. As these endovascular approaches continue improving, they limit demand for open surgical graft procedures.

This effect is especially visible in lower-leg procedures. In above-the-knee and below-the-knee disease, the continued use of balloons and stents directly constrains the growth of surgical graft segments. Even in cases where open surgery remains viable, physicians and patients often prefer less invasive approaches when clinically appropriate.

Atherectomy Devices

Atherectomy is another important limiter because it provides a minimally invasive alternative to surgical graft implantation in selected plaque-related disease. Mechanical, laser and cryoplasty-based debulking devices have expanded the range of endovascular options available to physicians, which reduces the number of cases moving directly to surgical graft repair.

This affects both market growth and market participation. As more lesion types become manageable with atherectomy and related endovascular methods, fewer companies and fewer hospitals need to rely heavily on surgical graft procedures. This steadily narrows the role of the market, especially in lower-limb applications.

Autologous Vein Grafts

Autologous vein grafts also limit the penetration of synthetic surgical grafts. In lower-limb bypass procedures, autologous veins often provide better long-term patency than synthetic alternatives. When suitable native vessels are available, surgeons may prefer autologous material rather than a manufactured graft.

This is a meaningful limitation because it reduces the number of cases available to synthetic graft manufacturers in the lower-limb segment. However, this constraint is not universal. Some patients, especially those with critical limb ischemia or with poor vessel quality, do not have suitable native veins. In those cases, synthetic surgical grafts remain necessary. Still, autologous vein use continues to cap growth potential in parts of the market.

Market Coverage and Data Scope

Quantitative Coverage

Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Qualitative Coverage

Market drivers and limiters, market size and growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.

Time Frame

Base year 2025, historical data to 2022 and forecasts through 2032.

Regional Coverage

North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa.

Data Types Included

Unit sales, average selling prices, procedure numbers, market size and growth trends.

This report is designed to give a practical view of the global surgical graft market by combining pricing and volume analysis with strategic context on how open vascular repair fits into the broader evolution of vascular treatment.

Markets Covered and Segmentation

• The report covers the Global Surgical Graft Market, further segmented by indication into:

Lower Limb Surgical Graft Market

This segment includes grafts used in lower-extremity bypass and related peripheral vascular reconstruction procedures.

Aorta Repair Surgical Graft Market

This segment includes grafts used in open aortic repair procedures, including major reconstruction in aneurysm and related disease cases.

Extra-Anatomical Bypass Surgical Graft Market

This segment includes grafts used in bypass procedures that reroute blood flow outside the normal anatomical pathway.

Each segment is analyzed using unit sales, average selling prices and total market value, with forecasts through 2032 and historical data to 2022. This segmentation reflects the key clinical use areas in which synthetic surgical grafts continue to play a relevant role.

Competitive Analysis

W.L. Gore held a strong position in the global surgical graft market in 2025, particularly in above-the-knee and below-the-knee surgical grafts. Its PROPATEN vascular graft gained strong traction due to a combination of distinctive design attributes, cost-effectiveness and solid clinical evidence. The heparin coating helps reduce thrombus formation on the graft surface, which supports physician confidence and contributes to the product's strong performance, especially in the below-the-knee subsegment.

Terumo remains another major competitor through its Gelsoft and Gelweave product lines. These devices use hydrolyzable gelatin in the coating, with Gelsoft made from sealed polyester and Gelweave made from woven polyester. Terumo's broad portfolio supports use across both cardiac and peripheral applications, giving the company flexibility and strong procedural relevance in multiple vascular settings. Its product breadth remains an advantage in a market where different open repair cases demand different graft characteristics.

Maquet is also a leading participant, especially in abdominal aortic aneurysm repair. Its HEMASHIELD product family remains among the most recognized AAA graft platforms in the market. HEMASHIELD Gold is known for high patency rates and improved biocompatibility, while HEMASHIELD Platinum offers a woven branch graft design with established healing performance and long-term effectiveness. The company also supports its market position with an extensive range of heparin-coated, antimicrobial and collagen-coated graft options.

Overall, the competitive landscape in the surgical graft market is shaped by material technology, coating strategy, long-term patency performance and the ability to serve different procedural indications. This is a mature market, so competitive strength depends less on disruption and more on clinical track record, trusted product families and sustained hospital relationships.

Technology and Practice Trends

One of the clearest trends in the surgical graft market is the broader shift toward endovascular and minimally invasive treatment. As stent grafts and other endovascular tools improve, they continue to reshape the vascular care pathway and reduce the number of open procedures in some indications.

Within the surgical graft market itself, coating technologies remain an important area of differentiation. Heparin-coated, collagen-coated and antimicrobial grafts continue to support product positioning by addressing thrombosis risk, healing performance and infection-related concerns.

Another important trend is procedural selectivity. Surgical grafts are increasingly reserved for cases where endovascular alternatives are less suitable, which means the market is becoming more concentrated around advanced disease states and specific patient populations rather than routine vascular treatment.

Finally, cost remains a practical trend driver. In regions with stronger budget pressure, surgical grafts continue to benefit from being less expensive than many premium endovascular alternatives, especially when follow-up costs are considered.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

137 pages of detailed market analysis, regional discussion and forecast data.

Methodology Appendix and Acronym Glossary.

Why This Report

Where are the most stable opportunities in the global surgical graft market through 2032?

How are endovascular alternatives affecting lower-limb, aortic repair and extra-anatomical bypass graft demand?

What role do hemodialysis growth and aneurysm prevalence play in sustaining the market?

How do hospital budget pressures and the total cost of endovascular repair influence treatment choice?

Which competitors hold the strongest positions in key graft categories, and how are product coatings shaping differentiation?

How can suppliers plan for growth in a market that remains clinically necessary but increasingly selective?

The Global Surgical Graft Market Report from iData Research answers these questions with detailed segmentation, pricing analysis, competitive intelligence and market forecasting. Use it to benchmark competitors, evaluate regional demand and support strategy in a mature but still important vascular device category.